Exploratory outcome measures include health-related quality of life, overall survival, and biomarker assessments. A broad cross-section of geographically and socioeconomically diverse clinical sites ...

ImmunityBio (IBRX) announced the Medicines and Healthcare products Regulatory Agency has validated and accepted the marketing authorization ...

MRI for the initial staging of MIBC is both feasible and beneficial in reducing treatment delays compared to TURBT, a new study shows.

Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...

Recent study results show that the single-target DNA methylation test performed with a negative predictive value of 97.6 percent.

The Decipher Bladder Genomic Subtyping Classifier found that patients with luminal tumors may have less aggressive disease.

A DNA methylation test is one of several noninvasive biomarkers test under investigation for the early diagnosis of bladder cancer.

The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with almost 17,000 fatalities. But now, a new gene therapy is giving patients ...

Bladder cancer is not the only cancer affected by the rule. Patients diagnosed with pancreatic, skin and thyroid cancers could lose access to genetic testing.

Tislelizumab plus low-dose nab-paclitaxel “demonstrated enduring efficacy while maintaining a manageable safety profile,” according to researchers.

The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with nearly 17,000 ...